GlassScriptPhysician profile
Sudha Reddy
NPI 1922023340
$2,431.63
in general payments reported to CMS, 2019-2025
28 companies · $476 in 2025
The $476 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $125 · 2021: $159 · 2022: $310 · 2023: $335 · 2024: $365 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,176.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $340.76 | 2019-2025 | Tezspire |
| Ucb, INC. | $260.31 | 2021-2025 | Nayzilam, Fintepla, Briviact |
| Neurelis, INC. | $225.03 | 2023-2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $189.65 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $182.35 | 2019-2020 | |
| Cardiovascular Systems INC. | $149.79 | 2019 | |
| Glaxosmithkline, LLC. | $127.51 | 2020-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.59 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $109.12 | 2023-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $95.86 | 2019 | |
| Jazz Pharmaceuticals INC. | $81.42 | 2025 | |
| Lilly USA, LLC | $79.87 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $64.97 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $49.59 | 2019-2020 | |
| Lundbeck LLC | $42.55 | 2023 | Rexulti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $39.16 | 2022 | |
| Neurocrine Biosciences, INC. | $35.13 | 2023-2024 | Ingrezza |
| Bayer Healthcare Pharmaceuticals INC. | $34.95 | 2022 | |
| Novo Nordisk INC | $30.13 | 2019 | |
| Boston Scientific Corporation | $30.02 | 2023 | Watchman Flx |
| Sumitomo Pharma America, INC. | $22.91 | 2023 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $22.47 | 2019 | |
| Exact Sciences Corporation | $21.46 | 2025 | Cologuard Collection Kit |
| Inogen, INC. | $20.07 | 2022 | |
| Aimmune Therapeutics, INC. | $18.95 | 2024 | |
| Alk-Abello, INC | $15.96 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.55 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.50 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudha Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.